Epithelial boost enhances antigen expression by vaccinia virus for the generation of potent CD8+T cell-mediated antitumor immunity following DNA priming vaccination
机构：[1]Department of Obstetrics and Gynecology, Tongren Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, China[2]Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, United States[3]Department of Gynecology and Obstetrics, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong province, China南方医科大学珠江医院[4]Department of Pathology, Department of Gynecology and Obstetrics, and Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, MD, United States[5]Departments of Pathology, Department of Obstetrics and Gynecology, Department of Molecular Microbiology and Immunology, and Department of Oncology. Johns Hopkins Medical Institutions, Baltimore, MD, United States[6]Papivax Biotech Inc., Taipei, Taiwan, ROC[7]Department of Pathology and Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, MD, United States
While both pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine and TA-HPV recombinant vaccinia viral vector-based vaccines have elicited HPV-specific CD8 + T cell responses in HPV16/E7-expressing tumor models, and been used as prime-boost regimen to enhance HPV-specific immune responses in humans (NCT00788164), the optimal route of administration for TA-HPV remains unclear. In a preclinical model, we examined the immunogenicity of priming with intramuscular pNGVL4a-Sig/E7(detox)/HSP70 followed by TA-HPV boost through different administration routes. We observed that priming twice with a pNGVL4a-Sig/E7(detox)/HSP70 followed by a single TA-HPV immunization boost through skin scarification generated the strongest antigen specific CD8 + T cell response in C57BL/6 mice. These data translate to tumor control and prolonged survival of treated mice. Our results provide rationale for future clinical testing of intramuscular pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine prime, TA-HPV vaccine skin scarification boost immunization regimen for the control of HPV-associated diseases.
基金：
This work was supported by the National Institutes of Health (NIH)
Cervical Cancer Specialized Program of Research Excellence (SPORE)
[P50CA098252]; (U.S.A.); NIH R01 grant [R01CA114425] (U.S.A.);
and NIH R21 grants [R21CA194896] and [R21AI109259]. This work
was also supported by Papivax Biotech Inc.
第一作者机构：[1]Department of Obstetrics and Gynecology, Tongren Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, China[2]Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, United States
通讯作者：
通讯机构：[2]Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, United States[6]Papivax Biotech Inc., Taipei, Taiwan, ROC[7]Department of Pathology and Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, MD, United States[*1]Papivax Biotech Inc., 9F-1, No. 57, Section 3, Min-Shen East Road, Taipei 10478, Taiwan, ROC.[*2]Departments of Pathology and Oncology, The Johns Hopkins University School of Medicine, CRB II Room 307, 1550 Orleans Street, Baltimore, MD 21231, USA.
推荐引用方式(GB/T 7714)：
Qiu Jin,Peng Shiwen,Ma Ying,et al.Epithelial boost enhances antigen expression by vaccinia virus for the generation of potent CD8+T cell-mediated antitumor immunity following DNA priming vaccination[J].VIROLOGY.2018,525:205-215.doi:10.1016/j.virol.2018.09.019.
APA：
Qiu, Jin,Peng, Shiwen,Ma, Ying,Yang, Andrew,Farmer, Emily...&Hung, Chien-Fu.(2018).Epithelial boost enhances antigen expression by vaccinia virus for the generation of potent CD8+T cell-mediated antitumor immunity following DNA priming vaccination.VIROLOGY,525,
MLA：
Qiu, Jin,et al."Epithelial boost enhances antigen expression by vaccinia virus for the generation of potent CD8+T cell-mediated antitumor immunity following DNA priming vaccination".VIROLOGY 525.(2018):205-215
